Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enavogliflozin in Severe Aortic Stenosis Patients Post-TAVR With HFpEF
NCT05672836Phase 4Recruiting
- Sponsor
- Duk-Woo Park
- Start
- Dec 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of enavogliflozin in aortic valve stenosis, heart failure with preserved ejection fraction (HFpEF), sponsored by Duk-Woo Park. Started Dec 2024; status: recruiting.
02
Drugs
enavogliflozin
03
Conditions
aortic valve stenosisheart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05672836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672836.